Introduction {#Sec1}
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Proliferative vitreoretinopathy (PVR) remains the major cause of ultimate surgical failure in patients with rhegmatogenous retinal detachment \[[@CR9], [@CR19]\]. Retinal pigment epithelium (RPE) cell dispersion and inflammatory changes secondary to breakdown of the blood--retinal barrier (BRB) have been implicated as important pathogenetic mechanisms in the development of PVR \[[@CR4], [@CR6], [@CR7], [@CR17]\].

Studies in animals \[[@CR5], [@CR18]\] have reported that intravitreal corticosteroids may be useful in the prevention of proliferative vitreoretinopathy. Clinical reports have suggested the same effect using either systemic \[[@CR15]\] or intravitreal \[[@CR31]\] steroids. This was mainly attributed to their attenuating effect on blood--retinal barrier breakdown and their inhibiting effect on proliferation of RPE cells and fibroblasts, which are thought to be transformed RPE cells, and as myofibroblasts responsible for the contractile properties of PVR membranes.

Studies in animals have suggested that pretreating with steroids was more effective in PVR prevention than treatment started at the time of injury or later \[[@CR5]\]. Adequate intraocular concentrations of corticosteroids at the time of surgery might reduce the blood--retina barrier breakdown induced by the surgical trauma during cryotherapy, drainage of subretinal fluid, or intravitreal gas injection, and thereby decrease the incidence of PVR.

Weijtens et al. showed in patients that among external routes of administration, a subconjunctival injection of dexamethasone resulted in the highest intravitreal and subretinal fluid concentrations \[[@CR25], [@CR26], [@CR28]--[@CR30]\].

Therefore we wished to study, in patients undergoing conventional scleral buckling retinal detachment surgery, whether a subconjunctival injection of dexamethasone prior to surgery would decrease postoperative blood--retinal barrier breakdown as measured by laser flare photometry.

Materials and methods {#Sec2}
=====================

Consecutive patients admitted to the Rotterdam Eye Hospital with a rhegmatogenous retinal detachment scheduled for scleral buckling were included in the study.

Exclusion criteria were therapy with systemic or local steroids, glaucoma, diabetes, and other vascular retinopathies. This prospective, randomized, placebo-controlled, double blind study had been approved by the Institutional Review Board (NRT 194, ISRCTN31308983).

**Preoperative investigation** All patients underwent a comprehensive ophthalmological examination, including best-corrected visual acuity tested with an EDTRS chart. Specific items were noted and entered into a database: lens status (phakic or pseudophakic), the presence of vitreous blood, number of quadrants of detached retina, presence and number of horseshoe tears, presence of PVR according to 1983 classification \[[@CR1]\], as well as aqueous laser flare meter measurements (Kowa Company, Ltd, Tokyo, Japan). Patients were examined 30 minutes after mydriasis with 5% phenylephrine and 1% tropicamide, and always before the application of fluorescein for intraocular pressure measurement. For each eye, five measurements were averaged.

**Surgical Technique** Six hours before the planned surgery, all patients received under topical anaesthesia (cocaine and oxybuprocaine eye drops) a subconjunctival injection 0.5 ml placebo NaCl (Delftse Apotheek, Apotheek Westblaak), or 0.5 ml dexamethasone diphosfate 20 mg/ml (Delftse Apotheek, Apotheek Westblaak). A 30-gauge needle was used, 4 mm from the limbus, with closure of the injection site by a cottonwool tip for 10 seconds. Randomization had been performed by opening an envelope with study medication that contained either verum or placebo, of which our trial-pharmacist held the code; therefore, surgeons and technicians alike were blinded to the nature of the subconjunctival injection. All patients underwent a standard scleral buckling procedure as described before \[[@CR22], [@CR23]\]. A silicone band was placed under the four rectus muscles at the presumed area of the vitreous base, and the sclera under retinal tears and breaks was indented with either a circumferential (278, 277, 287 Mira Silastic) or radial (7.5 mm sponge) buckle. Subretinal fluid was drained in all patients. Retinopexy of the tears or breaks was done by cryocoagulation during surgery, or with an argon laser mounted on a slit lamp between 2 and 6 weeks after the surgery, according to the surgeons' preference. In some patients, an air or gas (air/SF6) tamponade was used. All patients received a 2 mg dexamethasone and 1 mg gentamycin subconjunctival injection at the end of the surgery.

**Follow-up** All patients received the same postoperative treatment, prednisolone acetate 1% eyedrops in a tapering dose over 6 weeks. ETDRS vision, a fundus exam and laser flare measurements were taken at 1, 3 and 6 weeks.The treatment effects of dexamethasone versus placebo on flare were analyzed after logarithmic transformation of flare (photon counts/ms). Hence, effects were specified as percentage differences in photon counts/ms. Mixed model ANOVA was used to estimate and test for statistical significance the effects on flare of week (weeks 1, 3 and 6), treatment (dexamethasone, placebo), and their interaction. The baseline measurement of flare at week 0 was entered as covariable in the model, along with its interaction with week. No structure was imposed on the (co)variances of the three repeated measurement of flare.

Results {#Sec3}
=======

A total of 34 patients (19 males/ 15 females) were included from 1 February 2003 to 1 February 2004. The age of the patients ranged from 18 to 76 years (mean 54 years). Follow-up ranged from 6 to 8 months. Six patients did not complete the study as planned. One patient had a redetachment due to an undetected tear within the first weeks, and five patients missed two or more of their laser flare follow-up visits; none of these five patients suffered new breaks or a redetachment.

Of the remaining patients, 15 were in the placebo group and 13 in the dexamethasone group. The various baseline characteristics, such as preop vision, macula on or off, quadrants involved, type of breaks, or variables depending on the surgical procedure such as cryocoagulation or postoperative laser, were equally distributed between the dexamethasone-treated patients and the placebo group (Table [1](#Tab1){ref-type="table"}). At the last examination, two patients given placebo and two patients given dexamethasone had an intraocular pressure between 20 and 25 mmHg. Table 1Baseline characteristics of the two groups AgeRefrIOLPreop visionPreop PVRMaculaQuadrantsHolesHorseshoe tearsSurgeonLaserCryoDexa patients 165plan0.016off31Ex 221plan1.6on21Cx 344nn0.1off22Bx 472plan0.003off22Cx 560-50.25off11D 656-50.016off21Dx 766plan0.016off21Dx 840-30.016off22Cx 947-101.0on11Dx 1071-3+0.003off32Bx 1149-90.15off11Ex 1265nn0.25off21Dx 1381plan0.7Aon21CxPlacebo patients 177-20.003off3Ex 255plan0.016off31Cx 361-41.0on11Dx 447-61.0on11Ex 529-30.25Aoff12Cx 659-81.0on11Bx 740-.70.7part21Dx 864plan0.003C1off21Bx 956-50.003off21Cx 1062-60.003off21Cx 1117plan0.6part1dialysisDx 1230+20.5part11Bx 1359-71.0on11Bx 1471nn0.1off22x 1522-61.0on11Axrefr: refractive errorplan: plano refractionIOL: intraocular lensnn: not notedpart: partially off/partially attached

In the placebo group, laser flare measurements on average increased during the first week and decreased thereafter. In the dexamethasone group, there was a steady decrease as from week 0 (Table [2](#Tab2){ref-type="table"}, summary raw data). The mixed model ANOVA yielded the following results. The treatment effect on flare of dexamethasone versus placebo differed significantly between the three weeks (*P* = 0.007). The effect of baseline flare on flare during treatment also decreased significantly across the 3 weeks (*P* = 0.019). Only at week 1 was a significant reduction of dexamethasone relatively to placebo seen: flare was 48.3% lower under dexamethasone, adjusted for baseline flare (95% CI: 72.1% lower to 4.4% lower; *P* = 0.037); see the mixed model ANOVA estimates in Table [2](#Tab2){ref-type="table"}. Table 2Laser flare measurements (counts per seconds) at four visits, and their relative percentage in patients treated with dexamethasone when compared to patients treated with placeboWeekTreatmentSummary raw dataMixed model ANOVA estimates*N*MedianMin.Max.% dexa vs placebo95% CI*P*-value0Placebo1610.22.494.0Dexa1310.47.795.61Placebo1616.73.156.9Dexa128.11.058.6-48.3%-72.1% to -4.4%0.0173Placebo159.62.216.1Dexa127.13.148.9+2%-37.8% to +67.2%0.946Placebo155.70.914.0Dexa126.21.612.4+17.6%-35.1% to +113%0.58

Discussion {#Sec4}
==========

Intravitreal dexamethasone has been shown to reduce the number of tractional detachments in experimental animal models of PVR by cell-injection \[[@CR18], [@CR20]\]. Studies in animals and patient have suggested that pretreating with steroids was more effective in PVR prevention than treatment started at the time of injury or later \[[@CR5]\]. It was speculated that the decrease of BRB breakdown and inhibition of the proliferation of RPE cells accounted for this effect. Dexamethasone has a biphasic effect on RPE cell proliferation in vitro, i.e. rather a stimulatory effect with lower concentrations (ng per ml) \[[@CR12], [@CR32], [@CR33]\], and an inhibitory effect on proliferation of RPE in vitro at relatively high concentrations (mg per ml, not reached by peribulbar or systemic administration, only by intravitreal injection).

Corticosteroids bind to intracellular receptors and act on inflammation by inhibiting the synthesis of immunoregulatory proteins such as cytokines. The magnitude of this response is directly proportional to the number of occupied steroid receptors and is therefore dose-dependant \[[@CR3]\]. Given the studies by Weijtens et al. in patients with rhegmotogenous retinal detachments, macular puckers and macular holes, which showed that a subconjunctival dexamethasone injection would result in optimal concentrations in the vitreous (72.5 ng/ml after 2.5 mg dexamethasone \[[@CR25]\]) and the subretinal fluid (367 ng/ml after 2.5 mg dexamethasone \[[@CR27]\]) between 3 and 6 hours after injection; and assuming that the time interval between binding to the steroid receptor and transcription of effector proteins would take less than 2 hours, we timed the subconjunctival injection 5 to 6 hours before surgery. It may well be that only direct steroid-receptor ligand prevention of nuclear factor kappa B pro-inflammatory effect is acting within this time interval \[[@CR8]\]. The estimated dexamethasone concentration levels of 700 to 1000 ng/ml reached with our injection would be effective in decreasing BRB by inducing tight-junction formation \[[@CR2]\] and the modulation of cytokine release\[[@CR11]\], but not for cell growth inhibition \[[@CR12], [@CR16], [@CR32], [@CR33]\].

The disadvantage of using dexamethasone is its short half-life, limiting the time interval in which the drug can be used to minimize the surgically induced inflammation. For clinical purposes, a longer-acting steroid would allow a more flexible preoperative administration treatment moment, as well as a longer treatment effect, but it would be at the price of a higher incidence of raised intraocular pressure and a lower subretinal and vitreous concentration at the time of surgery. To ensure a continuous affective steroid concentration following preoperative priming by a subconjunctival dexamethasone injection, pre-operative intravitreal injection of longer-acting triamcinolone, or a sustained release implant might be an feasible option \[[@CR14], [@CR34]\].

A drawback of our study was the small number of patients enrolled. By changes in admission policy right at the start of our study, patients were no longer admitted the day before surgery but were treated on an ambulatory basis. Potential study patients were asked to come in at least 6 hours earlier then the normal admission time, which was a significant inconvenience and reduced the number of patients willing to participate in the study. Therefore, we could only use a quantitative surrogate marker, i.e. laser flare, as a measurement of BRB breakdown, instead of the originally intended rate of PVR.

Laser flare photometry, however, allows precise and non-invasve quantification of the aqueous protein content. Although laser flare photometry has been used mainly to study anterior segment inflammation, it has been shown to be useful in monitoring posterior segment disease \[[@CR10], [@CR13], [@CR21], [@CR23], [@CR24]\].

This study showed that a single injection of dexamethasone, injected at an estimated optimized time interval preoperatively, significantly decreased blood--retinal barrier breakdown at 1 week induced by a scleral buckling procedure. We cannot exclude, however, that a similar effect would have been achieved by supplying the same dose at the time of surgery or with a longer interval before surgery. To answer that comprehensively, a four-armed study would have been necessary. Nevertheless, our findings may help in designing a feasible, optimal perioperative steroid regime, which might include a sustained release device or intravitreal injection at the end of conventional surgery or, in the case that vitrectomy is chosen to treat the retinal detachment, steroids in the peroperative intravitreal infusion. However, surgically induced inflammation is only one risk factor among others in the development of PVR. Larger studies including greater numbers of patients, a more sustained dexamethasone regime, and longer follow-up are needed to demonstrate whether pharmacologically decreasing the blood--retina barrier breakdown ultimately may lead to a lower incidence of PVR.
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